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Abstract
Background: Loss of GABA-mediated pre-synaptic inhibition after spinal injury plays a key role in the progressive increase in
spinal reflexes and the appearance of spasticity. Clinical studies show that the use of baclofen (GABAB receptor agonist),
while effective in modulating spasticity is associated with major side effects such as general sedation and progressive
tolerance development. The goal of the present study was to assess if a combined therapy composed of spinal segment-
specific upregulation of GAD65 (glutamate decarboxylase) gene once combined with systemic treatment with tiagabine
(GABA uptake inhibitor) will lead to an antispasticity effect and whether such an effect will only be present in GAD65 gene
over-expressing spinal segments.
Methods/Principal Findings: Adult Sprague-Dawley (SD) rats were exposed to transient spinal ischemia (10 min) to induce
muscle spasticity. Animals then received lumbar injection of HIV1-CMV-GAD65 lentivirus (LVs) targeting ventral a-
motoneuronal pools. At 2–3 weeks after lentivirus delivery animals were treated systemically with tiagabine (4, 10, 20 or
40 mg/kg or vehicle) and the degree of spasticity response measured. In a separate experiment the expression of GAD65
gene after spinal parenchymal delivery of GAD65-lentivirus in naive minipigs was studied. Spastic SD rats receiving spinal
injections of the GAD65 gene and treated with systemic tiagabine showed potent and tiagabine-dose-dependent alleviation
of spasticity. Neither treatment alone (i.e., GAD65-LVs injection only or tiagabine treatment only) had any significant
antispasticity effect nor had any detectable side effect. Measured antispasticity effect correlated with increase in spinal
parenchymal GABA synthesis and was restricted to spinal segments overexpressing GAD65 gene.
Conclusions/Significance: These data show that treatment with orally bioavailable GABA-mimetic drugs if combined with
spinal-segment-specific GAD65 gene overexpression can represent a novel and highly effective anti-spasticity treatment
which is associated with minimal side effects and is restricted to GAD65-gene over-expressing spinal segments.
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Introduction
Spinal cord injury (traumatic or ischemic) may lead to the
development of clinically-defined spasticity and rigidity [1,2]. One
of the underlying mechanisms leading to the appearance of
spasticity after spinal injury is believed to be the loss of local
segmental inhibition and the resulting: i) increase in tonic
motoneuron firing [3,4], ii) increase in primary afferent input
during muscle stretch [5], and/or iii) exacerbated responses to
peripheral sensory stimulation (i.e., allodynia) [6,7]. Loss of
GABA-mediated presynaptic, recurrent and reciprocal postsynap-
tic inhibition [3] as well as the loss of its inhibitory effect in flexor
afferent pathways has been shown to represent one of the key
mechanisms [8,9,10,11].
Interestingly, however, previous studies have shown a significant
increase in spinal parenchymal GAD67 expression in lumbar
spinal segments in Th12 transected cats [12]. Similarly, an
increased density of inhibitory boutons apposing a-motoneuron
membranes has been shown in adult rats with midthoracic spinal
cord transection performed at postnatal day 5 [13]. These data
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spinal interneurons or increase in the number of inhibitory
contacts with a-motoneurons after spinal trauma, in the absence of
a specific inhibitory neuron-driven activity, is not sufficient to
prevent the development of spasticity/hypereflexia. In addition to
the role of decreased inhibition, several other potential mecha-
nisms have been shown to contribute to the development of
spasticity after spinal trauma, including: i) progressive increase in
a-motoneuronal 5-HT2C receptor activity which became sponta-
neously active in the absence of brain-derived serotonin [14], or ii)
the down regulation of the potassium-chloride co-transporter
KCC2 in motoneurons and resulting switch to GABA-mediated
depolarization [3]. Jointly, these data indicate that the mechanism
leading to the development of spasticity after spinal injury
(traumatic or ischemic) is complex and can vary depending on
the model used as well as the age of experimental animals when
the injury is induced.
Clinical pharmacological-treatment studies show that the use of
systemic or spinally-administered baclofen (GABAB receptor
agonist) represents the most potent anti-spasticity pharmacological
treatment. While effective in modulating spasticity of different
etiologies including spinal trauma, amyotrophic lateral sclerosis or
central stroke, major side effects such as general sedation and
progressive tolerance development often limit its chronic use
[15,16,17]. The use of systemically-administered GABA-mimetic
compounds such as tiagabine (GABA reuptake inhibitor) shows
only a weak or no anti-spasticity effect in clinically-acceptable
doses [18], which correlates with a relatively modest potentiation
of brain [19,20] or spinal parenchymal GABA release after
systemic delivery (current data). In addition, currently available
spinal drug delivery systems (such as epidural or intrathecal
delivery) do not permit a spinal segment-restricted therapeutic
effect. Because the origin of spasticity affecting individual muscle
groups can be somatotopically mapped to specific spinal segments,
the development of segment-targeted anti-spasticity treatments
would represent a clear advantage over current therapeutic
approaches by reducing unwanted side effects.
We therefore analyzed: i) if a combined treatment composed of
spinal segment-specific upregulation of GAD65 (glutamate-
decarboxylase) gene and systemic delivery of tiagabine (GABA
uptake inhibitor) in rats with ischemia-induced spasticity will lead
to an antispasticity effect, and ii) whether such a combined
treatment will be specific for GAD65 gene overexpressing spinal
segments.
Results
Loss of GABA-ergic interneurons and upregulation of
a-motoneuronal GABA B R1 and R2 receptor in animals
with ischemic spasticity
We first quantified the loss of GABA-ergic neurons and bouton-
like terminals in laminae VII and IX of lumbar spinal cord
sections taken from spastic and sham-operated control animals. In
comparison with control animals spastic animals had 50% less
GABA-ergic neurons (average 39.0613.4 vs. 19.564.2 per
section; p,0.01; Fig. 1A, B) in lamina VII. In those same
sections, GABA-ergic contact with a-motoneurons was also
assessed, revealing a significant reduction in spastic animals
(Fig. 1D-white arrows): 19.460.9 GABA/Syn-immunoreactive
(IR) boutons contacting each motoneuron soma in control tissue
compared to 10.160.8 in animals with spasticity (p,0.01;
Fig. 1C, D). We next examined the number of GAD65 or
GAD67 bouton-like structures that contacted VGluT1-IR primary
afferent terminals in lamina IX (i.e. the site of GABAergic
presynaptic Ia afferent inhibition). In control animals 26.764.2%
of primary afferent terminals had clear GAD65 contact,
compared to only 5.3%61.2% in ischemia-injured tissue
(p,0.001; Fig. 1E, F). No statistical difference was noted in
the number of VGluT1 terminals that had GAD67 contact
(25.364.8% in control vs. 15.264.3% in ischemic-spastic). No
overall change in the number of VGluT1-IR terminals was noted
in lamina IX (40.568.2 for control vs. 41.766.9 for ischemic-
spastic). In the subgroup of VGluT1-IR structures that had
GAD65 contacts (that is ignoring those with zero GAD65
contact), an average of 3.960.1 GAD65-IR boutons contacted
each VGluT1 terminal in control sections. In spastic animals this
number was reduced to 2.660.3 (p=0.003). Similar analysis of
GAD67 contact with VGluT1 terminals showed a trend towards
reduction in animals with spasticity (1.860.1 in control vs.
1.260.06 in ischemic-spastic; p=0.08). Western blotting of whole
tissue homogenates from the lumbar spinal cord showed that,
compared to control tissue, GAD65 protein was reduced by
2665% (p=0.045), and GAD67 by 3266% (p=0.017; Fig. 1G,
H) in ischemic-spastic animals. We next analyzed the presence of
GABA B R1 and R2 receptors on lumbar a-motoneurons using
immunofluorescence staining in control animals and animals at 3
months after induction of ischemic spasticity (n=3). In control
animals a sparse punctate-like GABA B R1 and R2 immunore-
activity was identified in a-motoneurons. In contrast, animals
with spasticity had a clear increase in GABA B R1 and R2
immunoreactivity on a-motoneuron membrane and in cytoplasm
(Fig. 1 I, J, L, M). Densitometric image analysis showed a
significant increase for both GABA B R1 and R2 receptor
punctata in animals with spasticity if compared to controls
(p,0.05; Fig. 1K, N).
Animals with spinal ischemic injury showed progressive
development of extensor-type paraplegia with components of
muscle spasticity and rigidity. To assess the presence of
spasticity, ankle resistance and EMG activity in gastrocnemius
muscle was measured during computer-controlled ankle dorsi-
flexion. Compared to control animals, a clear increase in muscle
resistance and EMG activity in spastic animals was measured at
7–60 days after ischemic injury (Fig. 1O, P). In previous studies
we have demonstrated a potent anti-spasticity effect after
intrathecal baclofen delivery [21]. Jointly these data demonstrate
that a selective loss of GABA-ergic segmental inhibition is the
primary mechanism leading to the appearance of muscle
spasticity and rigidity resulting from spinal ischemic injury.
Accordingly, we hypothesized that an increase in the local spinal
GABA-ergic tone (as achieved by spinal GAD65 gene delivery or
intrathecal GABA delivery) in previously injured spinal segments
should improve local inhibition and lead to amelioration of
spasticity.
Release of biologically active GABA from GAD65 over-
expressing rat spinal cord primary cells or human fetal
spinal cord astrocytes
We next prepared and tested the efficacy of lentivirus-mediated
GAD65 overexpression in primary rat spinal cord culture and
resulting increase in extracellular GABA release. Cells were
infected with HIV1-CMV-GAD65, HIV1-CMV-GAD65-GFP or
HIV1-CMV-GFP lentivirus (LVs). At intervals longer than 3–4
days, clear GFP expression was seen in cells infected with GFP-
tagged LVs (Fig. 2A). In HIV1-CMV-GAD65-GFP–infected
cells, GFP expression showed colocalization with GAD65
(Fig. 2B–D) and was primarily expressed in astrocytes (Fig. 2E–
G). Western blot analyses of cell cultures infected with each of the
constructs confirmed the presence of GFP, GAD65 or the
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30561Figure 1. Loss of segmental inhibitory GABA-ergic interneurons and increased expression of GABA B R1+R2 receptor in a-
motoneurons after transient spinal cord ischemia is associated with the development of chronic muscle spasticity. (A, B) Transverse
spinal cord sections taken from L2–L5 segments in control (A) or spinal ischemia-induced-spastic rat (B) at 24 h after intrathecal colchicine injection
and stained for GABA. Note an apparent loss of GABA-ergic interneurons in the intermediate zone in spastic rat (B; red circle). (C–F) Loss of GABA-
ergic interneurons corresponds with loss of GABA-IR and GAD65-IR boutons on membranes of persisting CHAT-IR a-motoneurons in animals with
ischemic spasticity (white arrows). (G, H) Western blotting for GAD65 and GAD67 in lumbar spinal cord samples taken from control animals (n=5–6)
or animals with developed ischemic spasticity (n=5–6), (*P=0.017; **P=0.045, unpaired t-test). (I–N) In comparison to control animals, an
upregulation in GABA B R1+R2 receptors in lumbar a-motoneurons was identified in animals with spasticity (compare Fig. 1I to Fig. 1J and Fig. 1L
to Fig. 1M). Quantitative densitometric analysis showed significantly increased densities for both receptor subunits in spastic animals (*-P,0.05;
Fig. 1K and Fig. 1N). (O, P) Measurement of EMG activity in gastrocnemius muscle and corresponding ankle resistance during computer-controlled
ankle rotation (45u/3 sec) in awake control sham-operated animals (O) and in animals with ischemic spasticity (P).
doi:10.1371/journal.pone.0030561.g001
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tions from cell cultures infected with HIV1-CMV-GAD65-GFP
(but not in HIV1-CMV-GFP-infected) showed a progressive and
significant increase between 3–14 days after LV infection (base-
line:150665 nmolR27 mmol69 at 7 days; p,0.01), (Fig. 2I).
Replacing the culture media at 14 days after infection with Ca
2+-
free buffer showed Ca
2+-independent increase in GABA release
and was seen in HIV1-CMV-GAD65-GFP (baseline 463
nmolR445695 nmol at 3 hrs; p,0.01) but not in HIV1-CMV-
GFP-infected cells (Fig. 2J).
We next tested if the GABA released from infected human fetal
astrocytes is biologically active by measuring changes in inward
current in patch-clamped human NT neurons. Human fetal
astrocytes were infected with HIV1-CMV-GAD65-GFP (Fig. 2K)
or HIV1-CMV-GFP (control) lentivirus and cultured for addi-
tional 7 days. After 7 days the culture media was replaced with
fresh HEPES-buffered Tyrode’s solution, incubated for 24 h and
conditioned media (ACM) harvested. ACM was then applied into
bath of whole-patch-clamped human NT neurons for 60 seconds.
As shown by the trace of Fig. 2 L the application of ACM
(measured GABA concentration: 8–14 mmol) induced inward
current i.e. response consistent with GABAA receptor-mediated
depolarization [22,23]. This response was similar to that measured
after application of 50 mM GABA (Fig. 2M). Application of ACM
harvested from astrocyte previously infected with control HIV1-
CMV-GFP lentivirus was without response (Fig. 2N).
Figure 2. Infection of rat primary spinal cord culture with HIV1-CMV-GAD65 or HIV1-CMV-GAD65-GFP lentivirus leads to a
preferential astrocyte GAD65 expression and release of biologically active GABA. (A) Rat spinal cord primary culture infected with HIV1-
CMV-GAD65-GFP lentivirus and stained with anti-GFP antibody at 4 days after lentivirus infection. (B–D) Co-staining of HIV1-CMV-GAD65-GFP-
infected cells with GAD65 antibody showed preferential GAD65 expression in GFP-IR cells. (E–G) Colocalization of GFP-IR with GFAP-IR in HIV1-CMV-
GAD65-GFP-infected astrocytes at 14 days after infection. (H) Western blotting for GFP or GAD65 in cell lysates taken from rat primary spinal cord
culture infected with HIV1-CMV-GFP (control), HIV1-CMV-GAD65-GFP, and HIV1-CMV-GAD65 lentivirus. (I) Extracellular GABA release measured in cell
culture media taken from rat primary spinal cord culture 3–14 days after HIV1-CMV-GFP (control) or HIV1-CMV-GAD65-GFP lentivirus injection. (J)
Progressive increase in extracellular GABA release measured in Ca
2+-free media 1–3 hrs after cell culture wash in HIV1-CMV-GAD65-GFP but not in
HIV1-CMV-GFP (control) lentivirus-infected cells (* P,0.01; paired t test). (K) Human fetal spinal cord astrocytes infected with HIV1-CMV-GAD65-GFP
lentivirus and stained with anti-GFP antibody at 7 days after lentivirus infection. (L) Changes in whole-cell inward current in cultured human NT
neurons after bath application of human astrocyte-HIV1-CMV-GAD65-GFP-conditioned media, (M)5 0mM GABA or (N) human astrocyte-HIV1-CMV-
GFP-conditioned media (control); (neurons clamped at holding potential (-) 60 mV).
doi:10.1371/journal.pone.0030561.g002
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tiagabine treatment leads to potent anti-spasticity effect
The above in vitro data suggest that the use of HIV1-CMV-
GAD65 lentivirus should similarly be effective in increasing GABA
synthesis after targeted spinal parenchymal delivery and that such
a local upregulation in GABA synthesis can lead to an anti-
spasticity effect. Similarly, topical-intrathecal delivery of GABA
should lead to a similar anti-spasticity effect.
To test this hypothesis we first injected GABA (1 mg)
intrathecally in rats with developed ischemic spasticity and the
effect on spasticity response measured during computer-controlled
ankle dorsiflexion for 60 min. No significant anti-spasticity effect
was seen (Fig. 3A, B). Because the baseline spinal extracellular
concentration of GABA is in pmol range (20–30 pmol) [24], but
mmolar (1–2 mmol) concentrations are required to exert its
receptor-mediated effect on in vitro cultured neurons [25] we
hypothesized that the activity of spinal GABA reuptake systems
[26,27] is likely responsible for the lack of sufficient GABA
accumulation in the synaptic cleft after even high dose GABA
administration. To address this we next tested the effect of
systemic treatment with the GABA uptake inhibitor tiagabine,
administered as a monotherapy or in combination with IT GABA.
Systemic treatment with 40 mg/kg/i.p. tiagabine alone was
without anti-spasticity effect (Fig. 3A, B). Because tiagabine has
good permeability across the blood brain barrier and increases
brain levels of extracellular GABA (2–3 fold increase) after
systemic administration of 11.5–21 mg/kg of tiagabine [19] we
speculate that the lack of functional effect in our model likely
reflects the documented loss of GABA-producing interneurons in
lumbar ischemia-injured segments. To validate this we next tested
the effect of combined systemic treatment with tiagabine (40 mg/
kg/i.p.) followed 15 min later by intrathecal injection of GABA
(1 mg). In this combined therapy a potent and highly significant
anti-spasticity effect was seen (Fig. 3A, B) the potency of which
was similar to our previously reported anti-spasticity effect after
intrathecal baclofen (GABAB receptor agonist; 1 mg) treatment
using the same spinal ischemia-induced spasticity model [21]. No
suppressive effect on upper extremity motor function was noted
and all animals showed continuing ability to move their upper
limbs and grab food pellets if offered.
Increase in spinal parenchymal GAD65 expression
provides a potent antispasticity effect if combined with
systemic tiagabine treatment
We next tested if spinal GAD65 overexpression will lead to
increased localGABAreleaseandifsuchareleasewillhave a similar
anti-spastic effect once combined with systemic tiagabine (1, 4, 10,
20 or 40 mg/kg) treatment. Spastic animals received a total of 20
bilateral injections of HIV1-CMV-GAD65-GFP (n=6) or HIV1-
CMV-GFP (n=6; control) lentivirus targeted into ischemia-injured
L2–L5 spinal segments and underwent spasticity assessments 7–21
days after virus delivery. In control HIV1-CMV-GFP-injected
spastic animals, systemic administration of tiagabine (40 mg/kg,i.p.)
was without effect (Fig. 3C, D). In contrast, in HIV1-CMV-
GAD65-GFP-injected rats, treatment with tiagabine led to a potent
and significant anti-spasticity effect. The peak effect was seen at
25 min after tiagabine administration and returned back to baseline
by 60 min (Fig. 3C, D;p ,0.01). Dose response analysis for
tiagabine showed that doses $4 mg/kg provided significant
(p,0.01) anti-spasticity effect at 15–25 min after tiagabine injection.
No detectable effect on upper limb motor function was seen after
tiagabine treatment and all animals showed continuing ability to
move their upper limbs and grab food pellets if offered.
In separate experimental sessions, changes in H-reflex ampli-
tudes evoked by high frequency stimulation was tested in
ketamine-sedated animals. In spastic animals previously injected
spinally with control lentivirus (HIV1-CMV-GFP; n=6) no
change in H-reflex amplitudes were seen up to 90 min after
tiagabine injections (Fig. 3E, F). In animals receiving spinal
injections of HIV1-CMV-GAD65-GFP lentivirus (n=6) a signif-
icant (p,0.05) reduction of the H-wave amplitude was measured
between 20–45 min after tiagabine injection and returned back to
baseline by 65 min (Fig. 3E, F). Similar significant suppression of
H-reflex activity in spastic patients after intrathecal baclofen
treatment was reported [28,29].
Spinal parenchymal injection of HIV1-CMV-GAD65
lentivirus leads to a significant increase in GAD65
expression and extracellular GABA release in rat and
minipig
To identify the spinal laminar distribution and cellular
specificity of HIV1-CMV-GAD65-GFP lentivirus-infected cells
and to validate if such overexpression could increase spinal
parenchymal GABA release, spastic rats received 20 bilateral
injections (0.5 ml each) of HIV1-CMV-GAD65-GFP (n=9) or
HIV1-CMV-GFP (n=9; control) lentivirus. At 14 days after
lentivirus injection, GABA concentrations were measured in LVs-
injected spinal segments using concentric microdialysis and
HPLC. The presence of GAD65-GFP expressing cells was
validated with immunofluorescence staining and quantified with
western blotting. Histological analysis showed a preferential
expression of the GAD65-GFP fusion gene in astrocytes
(Fig. 4A–C). Numerous GFP+/GAD65+ astrocytic processes
were identified in the vicinity of VGluT1-stained primary afferents
residing next to the membranes of persisting CHAT-IR a-
motoneurons (Fig. 4D, E). Western blot analyses of spinal cord
homogenates prepared from lumbar spinal cord of naive, spastic
non-treated, and spastic HIV1-CMV-GAD65-GFP-injected rats
showed significant loss of GAD65 expression in spastic non-treated
animals (if compared to naive control: see Fig. 1G) and the
presence of the GAD65-GFP fusion protein in HIV1-CMV-
GAD65-GFP-injected rats (Fig. 4F). Measurement of spinal
extracellular GABA concentration before and after tiagabine
(40 mg/kg; i.p.) administration showed a significant (p,0.05)
increase in naı ¨ve and HIV1-CMV-GAD65-GFP lentivirus-inject-
ed spastic animals if compared to spastic (non-injected) or spastic
HIV1-CMV-GFP lentivirus injected animals (Fig. 4G).
We next tested if spinal parenchymal injections of HIV1-CMV-
GAD65-GFP in a preclinical minipig model (naive non-injured
animals) would lead to a similar astrocyte-specific GAD65
upregulation. Guttingen-Minessota minipigs (n=2) received 20
bilateral injections of LVs (6 ml each injection; 10 M.O.I) and
survived for 1 or 2 months. Histological analysis of spinal cord
sections at 1 or 2 months after LVs injection showed similar
preferential astrocytic GFP-GAD65 co-expression in LVs injected
spinal cord segments (Fig. 4H).
Discussion
Decreased or completely lost activity of a facilitatory supraspinal
input into spinal GABA-ergic inhibitory interneurons and resulting
decrease in local segmental inhibition has been postulated as one
of the key mechanisms leading to the development of muscle
spasticity in patients with SCI [1,2]. Comparably, loss of spinal
inhibitory interneurons, as seen after transient episodes of spinal
cord ischemia leads to development of functionally defined muscle
spasticity and rigidity [21,30]. Independent of the insult nature
Spasticity and Spinal GAD65 Gene Upregulation
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pharmacology studies have shown a comparable and potent
antispasticity effect after systemic or spinal treatment with most
commonly used antispasticity agent baclofen (GABAB receptor
agonist) [31,32]. The primary site of baclofen-mediated hyperpo-
larizing action is believed to be at presynaptic Ia afferents [33,34].
One of the major limitations of systemic baclofen treatment,
however, is the lack of a localized spinal segment-restricted effect
and relatively high doses required to achieve clinically relevant
relief of spasticity frequently produce unwanted systemic side
effects such as sedation [35]. Direct spinal delivery of baclofen
using chronic intrathecal catheter provides a more site-restricted
effect with less pronounced systemic acitivity, however it requires
surgical intervention and ensuing complications associated with
chronic intrathecal catheterization such as cerebrospinal fluid leak
or infection has been described [32]. More importantly, limits of
Figure 3. Effective suppression of spasticity after combined therapy with systemic tiagabine and intrathecal injection of GABA or
spinal parenchymal GAD65 gene delivery. (A) EMG responses recorded from gastrocnemius muscle in spastic animals during computer-
controlled ankle dorsiflexion before and after systemic treatment with tiagabine (40 mg/kg; i.p.; n=6), intrathecal GABA (1 mg; IT; n=6) or combined
treatment with tiagabine+IT GABA (n=6). (B) Time-course of ankle resistance measured during ankle dorsiflexion at baseline and then in 5-min
intervals up to 80 min after treatments (* P,0.01; one-way analysis of variance-ANOVA, Bonferroni’s posthoc test; MPE-maximum positive effect). (C)
EMG responses recorded from the gastrocnemius muscle in spastic animals previously injected spinally with HIV1-CMV-GFP (control; n=6) or HIV1-
CMV-GAD65 (n=6) lentivirus and then treated with systemic 10 mg/kg or 40 mg/kg tiagabine. (D) Time-course of anti-spastic effect after tiagabine
treatment expressed as % of maximum possible effect in measured ankle resistance in HIV1-CMV-GFP or HIV1-CMV-GAD65-GFP lentivirus-injected
animals (* P,0.01; one-way analysis of variance-ANOVA, Bonferroni’s posthoc test; MPE-maximum positive effect). (E) Changes in H-wave amplitudes
recorded from interdigital muscles of the lower extremity during high frequency (20 Hz) sciatic nerve stimulation in animals previously injected
spinally with HIV1-CMV-GFP or HIV1-CMV-GAD65 lentivirus and then treated with 40 mg/kg tiagabine. (F) Time-course of changes in H-wave
amplitudes before and up to 90 min after tiagabine administration (red line-P,0.05; unpaired t test).
doi:10.1371/journal.pone.0030561.g003
Spasticity and Spinal GAD65 Gene Upregulation
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30561Figure 4. Spinal parenchymal injections of HIV1-CMV-GAD65-GFP lentivirus leads to increased GAD65 expression in infected
astrocytes in rat and minipig and is associated with increased extracellular GABA release after tiagabine treatment in rats with
ischemic spasticity. (A–C) Immunofluorescence images taken from a transverse lumbar spinal cord section of a spastic rat at 3 weeks after spinal
injection of HIV1-CMV-GAD65-GFP lentivirus. Sections were stained with GFP, GAD65 and GFAP antibody. (D, E) Confocal images demonstrating the
localization of GAD65-GFP (green) expressing processes in HIV1-CMV-GAD65-GFP-infected cells surrounding VGLUT1 (red)-IR primary afferent
terminals in the vicinity of persisting CHAT (blue)-IR a-motoneurons. (F) Western blot analysis for GAD65 in spinal cord homogenate taken from
lumbar spinal parenchyma of naive-control (column 1) spastic non-treated (columns 2 and 3) and spastic HIV1-CMV-GAD65-GFP-injected animal
(column 4). (G) Extracellular GABA concentration measured by intraparenchymal microdialysis in lumbar gray matter in naive (n=6), ischemic-spastic
Spasticity and Spinal GAD65 Gene Upregulation
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30561effective long-term use of IT baclofen include the development of
baclofen tolerance (i.e. progressive escalation of dose to achieve
consistent anti-spasticity effect) and withdrawal after an abrupt
termination of baclofen treatment [36,37].
Our study shows that animals with chronic ischemia-induced
spasticity have a significant reduction in spinal parenchymal
GAD65 expression which corresponds with a loss of GABA-ergic
interneurons and GABA+ terminals on a-motoneuronal mem-
branes and VGLUT1+ primary afferents. These data are in line
with the postulated role of decreased GABA-ergic activity in the
development of spinal ischemic spasticity. Spinal injection of
lentivirus encoding the GAD65 gene targeted into ischemia-
injured segments led to a significant increase in GAD65 expression
primarily in astrocytes and was associated with increased
extracellular GABA release once combined with systemic
tiagabine treatment.
Preferential expression of GAD65 gene in infected astrocytes (as
opposed to neurons) appears to provide a specific advantage with
respect to expected GABA mediated anti-spasticity effect. As we
have shown in vitro, infection of primary astrocytes led to a Ca2+
independent increase in extracellular GABA concentration.
Accordingly, it is expected that astrocyte-mediated GABA release
in the spinal parenchyma will be independent of the functionality
and connectivity of local neuronal inhibitory circuitry and will
specifically exert its hyperpolarizing effect on GABAB receptor
expressed on Ia afferents and/or a-motoneurons. The biological
activity of astrocyte-produced GABA was confirmed by its
depolarization-inducing effect on preferentially GABAA receptor-
expressing cultured hNT neurons (see Fig. 2).
Interestingly, the upregulation of spinal GAD65 expression in
the absence of any other treatment, however, had no detectable
anti-spastic effect. Previous studies have demonstrated that
GABA concentrations required for an effective GABAB receptor
activation is in the mmol range [25]. We speculate that while a
significant increase in GAD65 gene expression was achieved in
lentivirus-infected regions, efficient GABA metabolism mediated
in-part by the GABA reuptake system [26,27] prevented effective
GABA accumulation in the synaptic cleft and resulted in lack of
any functional effect. In contrast, animals that had received
lumbar injections of GAD65 lentivirus and were treated
systemically with tiagabine (a GABA uptake inhibitor) exhibited
a potent, dose-dependent reduction in spasticity of the lower
extremities up to 60 min after tiagabine administration. Impor-
tantly, no detectable effect on the motor performance of the
upper extremities (i.e. mediated by the activity of muscle groups
innervated by virus non-injected cervical segments) was seen. In
animals receiving lumbar injection of control GFP-tagged
lentivirus no antispasicity effect was seen after the treatment
with the same dose of tiagabine. Jointly these data show that the
use of tiagabine at doses which have no significant therapeutic
anti-spatic effect nor detectable side effects when used as a
monotherapy is highly effective in increasing local GABA-ergic
inhibitory tone in GAD65-overexpressing spinal cord regions; the
magnitude of such increased local inhibition provides a clinically-
relevant relief of spasticity.
We believe, that the ability of such combined therapy in which
systemically administered drugs (such as tiagabine) is effective in
regulating the activity of the therapeutic product (GABA) in
remote GAD65 gene-overexpressig sites can potentially have a
significant clinical implications.
First, the identity of specific spinal segments innervating the
affected spastic muscle groups can be neurologically mapped,
lateralized and selected for the segment/site-specific GAD65 gene
delivery.
Second, extensive clinical data show a potent anti-spastic
effect after intrathecal baclofen delivery and this effect is
independent on the spinal or supraspinal origin of spasticity
[17]. Thus, it is likely that spinal segmental GAD65 upregulation
once combined with systemic GABA uptake inhibitor treatment
will have a similar therapeutic effect in spasticity of supraspinal
and spinal origin.
Third, comparable site-specific delivery of GAD65-encoding
vectors targeting functionally/electrophysiologically-defined brain
epileptic foci can be performed. Previous data from other
laboratories have confirmed an improvement in the parkinsonian
behavioural phenotype and neuronal rescue after AAV-CBA-
GAD65 delivery into the subthalamic nucleus in 6-OHDA–
lesioned rats [38]. We speculate that proposed combination
treatments can lead to a more pronounced anti-epileptic effect
with less side effects such as general sedation.
Fourth, the serum half-life of tiagabine in human patients is
between 5–8 hrs (in contrast to 55 min in rats) and therefore
comparable duration of the antispasticty effect can be expected in
human patients once combined with spinal parenchymal GAD65
gene delivery [39,40,41].
Our current study employed a CMV-promoter-driven lentivi-
ral construct encoding GAD65 and astrocytes were the primary
cells expressing the GAD65-GFP transgene both in vitro and in
vivo. In addition to the rat spasticity model, testing the same
lentivirus in a preclinical non-injured minipig model showed a
similar expression profile and a stable expression of GAD65-GFP
protein in astrocytes at 1 and 2 months after spinal lentivirus
injections. This is consistent with recent studies that showed
preferential astrocytic expression of GFP in spinal gray matter
after direct parenchymal delivery of HIV1-CMV-EGFP lentivirus
in rat [42].
In addition to cell integrating gene transfer after the use
lentiviral vectors, there are reports of successful GAD65 gene
overexpression after AAV-GAD65 injections into subthalamic
nuclei. In those studies, persistent GAD65 expression was seen up
to 4–5 months after AAV-GAD65 injections [38]. More
importantly, recent systematic data demonstrate a high efficiency
of AAV-based gene delivery into rat or minipig striatum even after
a limited number of AAV injections (1–2 injections) [43,44,45,46].
Thus the use of AAV-based, genome-non-integrating GAD65-
encoding vectors appears to have the most favourable profile to be
used in clinical settings with fewer injections required to achieve
segment-specific GAD65 expression.
In summary we demonstrate that the treatment with the orally
bioavailable GABA-mimetic drug tiagabine if combined with
spinal-segment specific GAD65 overexpression is highly effective
in suppressing chronic muscle spasticity. This combined treatment
can represent a novel therapeutic approach to modulate chronic
spasticity in patients after spinal traumatic or ischemic injury.
(n=6), ischemic-spastic-HIV1-CMV-GFP (n=6) and ischemic-spastic-HIV1-CMV-GAD65-GFP (n=6) lentivirus-injected animals before and after systemic
tiagabine (40 mg/kg) injection. A significant increase in extracellular GABA concentration was measured at 20–40 min after tiagabine administration
in naive animals and ischemic-spastic animals previously injected spinally with HIV1-CMV-GAD65-GFP lentivirus (P,0.05; paired t test). (H) Confocal
images of transverse spinal cord section taken from a minipig lumbar spinal cord at 2 months after spinal HIV1-CMV-GAD65-GFP injections and
stained with GFP, GAD65 and CHAT antibody.
doi:10.1371/journal.pone.0030561.g004
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Ethics Statement and Institutional Animal Care and Use
Committee approvals
This study was approved by the University of California,
San Diego (UCSD) Internal Review Board (IRB), approval
ID#101323.
All animal studies were carried out under protocols approved by
the Institutional Animal Care and Use Committee at University of
California (approval Ids # S01193 and S07016) San Diego or of
the Czech Academy of Sciences (IAPG Libechov: approval ID#
5/2010) and were in compliance with The Association for Assessment of
Laboratory Animal Care guidelines for animal use. All studies were
performed in such a manner as to minimize group size and animal
suffering.
Induction of spinal ischemic spasticity in rat
Transient spinal cord ischemia (10 min) was induced as
previously described [47]. Briefly, in isoflurane (1.5–2%)-anesthe-
tized SD rats, a 2F Fogarty catheter (Am.V. Muller, CV 1035;
Baxter, Inc., Irvine, CA, USA) was passed through the left femoral
artery to the descending thoracic aorta to the level of the left
subclavian artery. Distal arterial pressure (i.e. below the level of
aortic occlusion) was monitored by cannulation of the tail artery
with PE-50 catheter. Spinal cord ischemia was induced by
inflation of the intra-aortic balloon catheter (0.05 ml of saline)
and concurrent systemic hypotension (40 mm Hg) induced by
blood withdrawal (10.5–11 cc into a heated (37uC) external
reservoir) via a 20- gauge polytetrafluoroethylene catheter placed
in the left carotid artery. The efficacy of the occlusion was
demonstrated by an immediate and sustained drop in distal blood
pressure. After 10-min ischemia, the balloon was deflated, and the
blood was reinfused. When the arterial blood pressure was
stabilized (20–30 min after reflow), the arterial lines were
removed, wounds closed and animals were allowed to recover.
In this spinal ischemic model on average 50–60% of animals
exposed to 10 min of aortic occlusion show development of
progressive muscle spasticity at 5–21 days after ischemia.
Identification of muscle spasticity in rats with spinal
ischemic injury
One to eight weeks after ischemia, animals were tested for the
presence of spasticity. Spasticity was identified as an increase in
ankle resistance during computer-controlled ankle dorsiflexion,
which correlated with increased EMG activity measured in the
gastrocnemius muscle during the same time frame. Direct
measurement of ankle resistance during computer-controlled
ankle dorsiflexion was performed as described previously [5].
Rats were individually placed in a plastic restrainer, and one hind
paw was securely fastened to the paw attachment metal plate,
which is interconnected loosely to the ‘‘bridging’’ force transducer
(LCL454G, 0–454 g range; or LCL816G, 0–816 g range; Omega,
Stamford, CT). After a 20 min acclimation period, rotational force
was applied to the paw attachment unit using a computer-
controlled stepping motor (MDrive 34 with onboard electronics;
microstep resolution to 256 microsteps/full step; Intelligent
Motion Systems, Marlborough, CT), causing the ankle to dorsiflex
(Fig. 1O). The resistance of the ankle was measured during 45u of
dorsiflexion lasting 3 sec (15u s
21), and data were collected directly
to a computer using custom software (Spasticity version 2.01;
Ellipse, Kosice, Slovak Republic).
To identify the mechanical component of measured ankle
resistance, all animals were anesthetized with 2.5–3% isoflurane at
the end of the experiment and the relative contribution of
mechanical vs. neurogenic component (isoflurane-sensitive) was
calculated. Data generated before and after treatment were
expressed as % of maximum possible effect of neurogenic
component contributing to measured resistance. Each recorded
value was the average of three repetitions. To record EMG
activity, a pair of tungsten electrodes was inserted percutaneously
into the gastrocnemius muscle 1 cm apart. EMG signals were
bandpass filtered (100 Hz to 10 kHz) and recorded before, during,
and after ankle dorsiflexion. EMG responses were recorded with
an alternating current-coupled differential amplifier (model DB4;
World Precision Instruments, Sarasota, FL) and stored on a
computer for subsequent analysis. EMG was recorded concur-
rently with ankle resistance measurement during dorsiflexion.
Intrathecal catheterization
In some animals intrathecal catheters were implanted into
lumbar intrathecal space [48]. Under isoflurane anaesthesia, an
8.5 cm PE-5 catheter (Spectranetics, Colorado Springs, CO)
connected to 4 cm of PE-10 was inserted into the intrathecal space
through an incision in the atlanto-occipital membrane of the
cisterna magna. The PE-10 arm was externalized on the neck for
bolus drug (GABA) delivery or for colchicine injections.
Construction and preparation of lentivirus vectors
Rat GAD65 cDNA, inserted into the EcoRI site of the
pBluescript-SK (Stratagene, CA), was obtained from Dr. A. Tobin
(UCLA) [49]. HIV1 vector backbone plasmid pHIV7 containing
the WPRE and cPPT sequences were obtained from Dr. J-K. Yee
(City of Hope) [50]. To construct the HIV1 vector expressing the
GAD65 cDNA from hCMV promoter, hCMV promoter was
isolated from pLenti6/V5-GW/lacZ (Invitrogen, CA) with ClaI-
EcoRV digestion and inserted into the ClaI-EcoRV sites of the
pBluescript-GAD65. The hCMV-GAD65 cassette was then
isolated and inserted into the Bam HI site of the pHIV7 and the
resulting plasmid was designated pHIV7-CMV-GAD65. Similar-
ly, to construct the HIV1 vector expressing GAD65-EGFP fusion
gene, the GAD65 cDNA was inserted downstream of the hCMV
promoter of the pEGFP-N1 (Clontech, CA) adjusting the reading
frame with the downstream EGFP gene. The hCMV-GAD65-
EGFP cassette was isolated and then inserted into the BamHI site
of the pHIV7 to create the HIV1 vector pHIV7-CMV-GAD65-
EGFP. A control HIV1 vector pHIV7-CMV-EGFP expressing
EGFP gene from the same hCMV promoter was constructed by
inserting the hCMV-EGFP unit isolated from the pEGFP-N1 into
the pHIV7.
Lentivirus vectors were produced by transient co-transfection of
HEK293T cells (Invitrogen, CA; Cat.No: R70007) maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% FCS.
293T cells in 150 mm dishes were co-transfected by the CaPO4-
DNA co-precipitation method with each HIV1 vector plasmid,
pLP1 and pLP2 (Invitrogen, CA), and pCMV-G [51]. Condi-
tioned media at day 1, 2 and 3 post transfection were collected,
filtered through a 0.45 mm filter, and concentrated by centrifuga-
tion at 7000 rpm for 16 hrs at 4uC with a Sorvall GS-3 rotor. The
resulting pellets were resuspended with buffer containing 10 mM
Tris HCl, pH 7.8, 1 mM MgCl2 and 3% sucrose.
Infectious titters of the HIV1 vectors were measured by real-
time Q-PCR using the HIV1-CMV-GFP vector (1610
29 iu/ml)
as the standard. HEK293T cells in a 6-well plate were infected
with serially diluted vector preparations in the presence of
polybrene (4 mg/ml). Infected cells were passaged once every 4
days and cell DNAs were prepared at day 14 post infection by the
DNeasy Blood & Tissue kit (Qiagen Science, MD). Real-time Q-
PCR was performed to measure the copy numbers of the provirus
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from the WPRE sequence and the final virus titters were adjusted
to 1610
29 iu/ml.
Lentiviral infection of primary spinal cord cultures
Spinal cords were isolated from embryonic day 14 (E14)
Sprague–Dawley rats (Harlan Sprague–Dawley Inc., Indianapolis,
IN). Cells were isolated using the papain dissociation system
(Worthington Biochemical Corp., Freehold, NJ), following the
manufacturer’s instructions with modification. Tissue was dissoci-
ated in 5 ml of papain dissociation solution by trituration, followed
by agitation for 20 min at 37uCi n5 %C O 2. The cell suspension
was centrifuged at 3006 g for 5 min and the cell pellet was
resuspended in Deact solution (albumin-ovomucoid inhibitor/
DNase solution). Resuspended cells were then layered on top of a
discontinuous density gradient of albumin-ovomucoid inhibitor
mixture and then centrifuged at 706g for 5 min. The cell pellet
was resuspended in 50 ml of 10 M.O.I. HIV1-CMV-GFP, HIV1-
CMV-GAD65 or HIV1-CMV-GAD65-GFP lentivirus and incu-
bated at 37uC for 10 min. Infected cells were then plated into
poly-d-lysine-coated chamber slides and cultured for 1–3 weeks in
growth medium (DMEM high glucose supplemented with 10%
FBS, 2 mM l-glutamine, B27 supplement and 100 U/ml penicillin
and 100 mg/ml streptomycin; GIBCO, Grand Island, NY). At 1–3
weeks some cells were washed with PBS 36and then fixed with
4% paraformaldehyde for 30 min at RT and later used for
immunofluorescence staining.
Measurement of extracellular GABA release in rat primary
spinal cord culture and human fetal astrocyte culture
Tissue culture media was collected from cultured rat spinal cord
cells at baseline and then at 3 days, 7 days and 2 weeks after
infection with HIV1-CMV-GFP, HIV1-CMV-GAD65 or HIV1-
CMV-GAD65-GFP lentivirus and filtered through 0.22 mm filter.
At 14 days cultures were washed with PBS solution 36 and
incubated in Ca
2+ free PBS for 3 hrs. Samples were collected at
baseline and then at 1, 2 and 3 hrs. All samples were analyzed for
GABA concentration using HPLC (HTEC-500; EICOM, Japan).
Human fetal astrocytes (ScienCell, Carlsbad, CA, USA) were
infected with HIV1-CMV-GAD65-GFP or HIV1-CMV-GFP
(control) lentivirus and cultured for additional 7 days in
DMEM/F12+10%FBS. After 7 days the culture media was
replaced with fresh HEPES-buffered Tyrode’s solution, incubated
for 24 h and conditioned media (ACM) harvested for GABA
measurement and for patch clamp experiment using cultured
human NT neurons (see following paragraph).
Patch clamp recordings
Human NT neurons (Layton Biosciences) [52] were co-cultured
with human fetal astrocytes (ScienCell, Carlsbad, CA, USA) using
DMEM/F12 +10% FBS for 3–4 weeks. The recording micropi-
pettes (tip resistance 4–6 mOm) were filled with internal solution:
135 mM K-gluconate, 4 mM MgCl2, 10 mM HEPES, 10 mM
EGTA, 4 mM Mg-ATP and 0.2 mM Na-GTP [pH 7.4].
Recordings were made using a MultiClamp 700B amplifier and
Digidata 1440A interface (Molecular Devices). Signals were
filtered at 10 kHz and sampled at 10 kHz. The whole-cell
capacitance was fully compensated. The bath was constantly
perfused with fresh HEPES-buffered saline: 140 mM NaCl, 5 mM
KCl, 10 mM HEPES, 1 mM EGTA, 3 mM MgCl2,1 0 m M
glucose [pH 7.4]. Cells were visualized using an OLYMPUS
BX51W1 fixed-stage upright microscope. Whole-cell recordings
were carried out at a holding potential of 260 mV in gap-free
mode. Cell were constantly perfused with extracellular solution
with flow rate 2 ml/min. Astrocyte-conditioned media (ACM) or
50 mmol GABA (Sigma) was applied to the bath solution when the
holding current was stable for at least 4 min. All recordings were
performed at room temperature.
Spinal parenchymal lentivirus injection in spastic rat and
naive minipig
Rats with identified spasticity were anesthetized with 1.5–2%
isoflurane (in room air), placed into a spinal unit apparatus
(Stoelting, Wood Dale, IL, USA) and a partial Th12–L1
laminectomy was performed using a dental drill (exposing the
dorsal surface of L2–L6 segments). Using a glass capillary (tip
diameter 80–100 mm) connected to a pressure-controlled micro-
injector (Stoelting), rats were injected with 0.5 ml of the HIV1-
CMV-GAD65-GFP (n=12) or HIV1-CMV-GFP (control; n=12)
lentivirus (10 M.O.I.). Animals received a total of 10 bilateral
injections. The duration of each injection was 60 s followed by 30-
s pause before capillary withdrawal. The injection was targeted
into central gray matter (laminae V–VII) (distance from the dorsal
surface of the spinal cord at L3 level: 1 mm) [53]. The
rostrocaudal distance between individual injections ranged
between 1000–1500 mm. After virus injections, the incision was
cleaned with 3% H2O2 and penicillin/streptomycin mixture and
closed in two layers. After LVs injections animals were allowed to
recover for minimum of 10 days before the effect of LVs injections
on the magnitude of spasticity was measured.
Minnesota-Gottingen minipigs (males; 18–23 kg; n=2) were
premedicated with intramuscular azaperone (2 mg/kg ; Biotika,
SK) and atropine (1 mg/kg; Biotika, SK) and then induced with
ketamine (20 mg/kg, i.v.). After induction, animals were intubated
with a 2.5F tracheal tube. Anesthesia was maintained with a 1.5%
isoflurane in 50/50% air -oxygen mixture at a constant 2 L/min
flow rate. Oxygen saturation was monitored throughout the
procedure using a pulse oximeter (Nellcor Puritan Bennett Inc.,
Ireland). To immobilize the lumbar spinal cord animals were
mounted into a spinal immobilization apparatus and the lumbar
portion of the animal was lifted 50 above the operating table to
eliminate spinal cord pulsation due to respiration [54]. A dorsal
laminectomy of L2–L5 vertebrae, corresponding to L3–L6 spinal
segments in minipigs, was then performed and epidural fat
removed using cotton swabs. The dura was left intact. To deliver
LVs, an XYZ manipulator (M325; WPI, Sarasota, FL, USA) was
used and mounted directly to the operating table. A Hamilton
syringe with a 30 gauge needle was then mounted into the
manipulator and connected to a microinjector (Stoelting) using
PE-50 tubing. To connect the PE-50 tubing to the Hamilton
syringe the plunger was removed and one end of the PE-50 tubing
was inserted 1 cm into the syringe and sealed with silicone.
Animals then received a total of 20 injections (10 on each side) of
HIV1-CMV-GAD65-GFP lentivirus (10 M.O.I.; 6 ml each)
targeted into intermediate zone (lamina VII) of L2–L4 segments
(distance from the dorsal surface of the spinal cord at L3 level: 3–
3.5 mm). The distance between individual injections was 1–
1.5 mm. All surgical interventions followed rigid aseptic proce-
dures. All materials were subjected to autoclaving or gas
sterilization. After LVs injections animals survived for 1 or 2
months.
Hoffmann reflex recording
H-reflex was recorded as previously described [21]. Under
ketamine anesthesia (100 mg/kg/hr, i.m.) the right hind limb of
the animal was secured and a pair of stimulating needle electrodes
was transcutaneously inserted into the surroundings of the tibial
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into the interosseous muscles between the fourth and the fifth or
the first and the second metatarsal right foot muscles. The tibial
nerve was stimulated using square pulses with increasing stimulus
intensity (0.1–10 mA in 0.5 mA increments, 0.1 Hz, 0.2 ms; WPI;
Isostim A320) and responses were recorded with an A/C-coupled
differential amplifier (Model DB4; DPI, Sarasota, FL). After the
M-max and H-max responses were identified the intensity of
stimulus which evoked H-max amplitudes were used in subsequent
high frequency (20 Hz) stimulation experiment. In HIV1-CMV-
GAD65-GFP (n=6) or HIV1-CMV-GFP (n=6) lentivirus-
injected animals a high frequency stimulation was performed in
5 min intervals for up to 90 min after tiagabine (40 mg/kg, i.p.)
injection. Changes in H-wave amplitude were then compared
between both lentivirus-injected groups.
Spinal cord microdialysis and extracellular GABA release
measurement
Spinal cord microdialysis was performed in naive (n=6),
spastic-non treated (n=6), spastic HIV1-CMV-GFP lentivirus-
injected (n=6) and spastic HIV1-CMV-GAD65-GFP (n=6)
lentivirus-injected animals. Rats were anesthetized with 2%
isoflurane, previous laminectomy site (in lentivirus injected
animals) re-exposed and concentric microdialysis probe (A-2-8-
02; cut off: MW 50, 000; EICOM, Japan) placed into central gray
matter between L3–L6 spinal cord segments. Microdialysis fiber
was perfused with artificial CSF at 2 ml/min and samples collected
on dry ice. After 120 min washout samples were collected in
20 min intervals before and after tiagabine (40 mg/kg, i.p.)
injections and analyzed for GABA using HPLC (HTEC-500;
EICOM).
Intrathecal administration of colchicine
To decrease axonal transport of GABA and increase its
concentration in the neuronal soma, control animals (n=3) and
animals with ischemic spasticity (n=3) previously implanted with
PE-10 intrathecal catheters received intrathecal bolus injection of
colchicine (10 ml, 1% in saline) 48 h prior to sacrifice. This
treatment was used to determine the presence or loss of GABA-
ergic neurons in animals with ischemic spasticity. These animals
were not used in any functional measurements.
In vivo perfusion fixation and tissue processing
At the end of the survival periods, animals were anesthetized
with pentobarbital (40 mg/kg; i.p.) and transcardially perfused
with heparinized saline (100 ml-rat; 5l-minipig) followed by 4%
paraformaldehyde in 0.1 M phosphate buffer (PB; 500 ml-rat; 5l-
minipig). The spinal cords were dissected and postfixed in the
same fixative overnight at 4uC. After postfixation tissue was
cryoprotected in graded sucrose solutions (10, 20 and 30%). For
GABA staining animals were perfused with 2% paraformaldehyde
+0.3% glutaraldehyde solution.
Immunofluorescence staining
A standard immunofluoresence staining protocol was followed.
After cryoprotection frozen coronal spinal cord sections (20–
30 mm) were cut. Free floating sections were placed in PBS (0.1 M;
pH=7.4) containing 5% normal donkey serum (NDS), 0.2%
Triton X-100 (TX), for 2 h at room temperature to block non-
specific background. This was followed by overnight incubation at
4uC with the following primary antibodies: mouse anti-
GAD65(1:500; Developmental Studies Hybridoma Bank, Univer-
sity of Iowa, Iowa City, IA); rabbit anti-GAD65 (1:1000,
Chemicon), mouse anti-GAD67 (1:1000, Chemicon), rabbit anti-
GFAP (1:500; Chemicon); mouse anti-VGLUT1-3 (1:2000;
Chemicon Inc.), goat anti-CHAT (1:100; Chemicon Inc.), mouse
anti-GABA (1:15000; Chemicon), guinea pig-anti GABA B R1
and R2 (1:2000; Millipore Inc.,), rabbit anti-synaptophysin (SYN)
(1:200; Novocastra Laboratory). After incubation with primary
antibodies, sections were washed 36 in PBS and incubated with
fluorescent-conjugated secondary donkey anti-rabbit, donkey anti-
mouse, donkey anti-goat and donkey anti-guinea pig antibodies
(Alexa 488, 594, 680; 4 ml/ml; Molecular Probes, Eugene, OR,
USA). All blocking and antibody preparations were made in
0.1 M PBS/0.2% TX/ in 5% normal donkey serum. For general
nuclear staining DAPI (1 ml/ml) was added to the final secondary
antibody solutions. After staining, sections were mounted on slides,
dried at room temperature and covered with Prolong anti-fade kit
(Molecular Probes). Stained sections were analyzed and photo-
graphed with epifluorescence microscope (AX70; Olympus) and
confocal microscope (Fluoview 1000, Olympus).
Quantitative analysis of GABA neurons, GAD65/67 and
VGLUT1 terminals and a-motoneuron-expressed GABA B
R1+R2 receptor in L2–L5 spinal segments
GABA-ergic cell bodies. Five sections from each animal
were stained for GABA and a blinded investigator counted all
GABA-positive neuronal bodies using UTHSCA Imagetool
(developed at the University of Texas Health Science Center at
San Antonio, Texas, USA); the same limits for pixel intensity and
structure size were set in all images analyzed.
VGluT1/GAD65/GAD67-positive terminals. Analysis was
performed according to Todd et al. [55] and Hughes et al. [56].
Briefly, 3 sections were selected from each rat (3 naive and 3
ischemic) and analysed by confocal microscopy (Leica
Microsystems, Bannockburn, IL) using a 1006 oil-imersion
objective with 26 zoom (2006 magnification, 75675 mm field
size). In all cases sequential scanning with the 488, 543, and
647 nm laser lines was used to capture two random scan fields (8–
10 optical layers, z-separation 0.5) in lamina IX with identical
confocal settings for all images. Firstly, using images constructed
from 2 optical layers, the total number of immunoreactive
structures in each scan field was counted using UTHSCA
Imagetool with the same limits for pixel intensity. Secondly, for
each VGluT1 terminal in the constructed image, the number of
GAD65 and GAD67 boutons in contact with each VGluT1-IR
terminal was counted by a blinded investigator. Thirdly, each
VGluT1-positive terminal identified in the constructed images was
classified as having contact with zero (no inhibitory contact) or 1 or
more GAD65/67 boutons (some inhibitory contact).
GABA-ergic input to motoneuron cell bodies. Three
sections from each animal were stained for GABA, synaptophysin
and ChAT and confocal microscope (Leica Microsystems,
Bannockburn, IL) images of lamina IX a-motoneurons were
captured using a 1006oil-immersion objective; the same settings
wereused to capture allimages. GABA-IR terminals were identified
and only those that were double-labelled with synaptophysin and in
contact with the motor cell soma (not associated processes) were
counted. A total of 89 or 58 cells were assessed from naive and
ischemic-spastic animals, respectively.
GABA B R1+R2 receptor in lumbar a-motoneur-
ons. Three sections were selected from each rat (3 naive and 3
spastic) and analysed using digital images captured with 206
objective (Leica BMX). The total number of GABA B R1 or R2
immunoreactive punctata in each NeuN+ a-motoneuron (cell body
size ,700 mm
2) in the ventral horn was counted using UTHSCA
Image tool with the same limits for pixel intensity. Population
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intensity was then calculated and used for statistical analysis.
Western blot analysis of GAD65 and GAD67 protein in rat
spinal cord
Samples of L2–L6 spinal cord segments were collected by
hydroextrusion from naive (n=3), spastic non-treated (n=3) and
spastic-HIV1-CMV-GAD65-GFP-injected animals (n=3). Har-
vested segments were cryo-sectioned (40 mm thick sections) and
lysed for 30 minutes using lysis buffer containing 50 mM Tris
(pH 7.4) (5429.3; Roth), 250 mM NaCl (3957.2; Roth), 5 mM
EDTA (E5134; Sigma), 50 mM NaF (S-1504; Sigma), 1 mM
Na3VO4 (S6508; Sigma) in 1% TritonH X-100 (T8532; Sigma) with
protease inhibitor cocktail tablets (Complete Mini, EDTA-free;
11836170001; Roche) and 1 mM phenylmethylsulphonyl fluoride
(PMSF; 837091; Roche). All samples were sonicated in a cold water
bath for 5 minutes, followed by centrifugation at 100006ga t4 uC
for 20 min. Total protein levels were determined by the BCA
Protein Assay method (23225, Thermo Scientific). Samples were
incubated with sample buffer (distilled water with 125 mM Tris-
HCl, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004%
bromophenol blue) at 95uC for 5 minutes and 15 micrograms of
total protein was loaded from each sample on the 10% gel
acrylamide gel. After electrophoresis, proteins were transferred to
nitrocellulose membrane (Trans-Blot, 0.45 micrometer, Bio-Rad,
CA) using a semidry blotting system (TE70XP, Hoefer, USA). The
membrane was blocked with 5% nonfat dry milk (NFDM) in Tris-
buffered saline with 0.5% Tween 20 (TBS-T, pH 7.4), incubated
with the primary antibody (mouse anti-GAD65 or-GAD67
(Hybridoma Bank, Iowa) diluted 1:200 in 5% NFDM in TBS-T)
overnight at 4uC on a shaker. The next day, the membrane was
washed 3 times in TBS-T and consequently incubated in donkey
anti-mouse Ab HRP conjugate, (Jackson Lab, full source info)
diluted 1:10000 in 5% NFDM in TBS-T for one hour at RT with
gentle shaking. SuperSignal West Pico Chemiluminescent Substrate
(34077, Pierce) detection system was used for visualization. Western
blotting signal was quantified by determining the grey values of
given band using the ImageJ software.
Statistical analysis
Statistical analysis of spasticity data was performed with one
way ANOVA followed by Bonferroni post hoc test. H-reflex data
were analyzed using un-paired t-test. The GABA release data were
analyzed using paired t-test. Statistical analysis of GABA-ergic
neurons and GABA+; GAD65/67 terminals was performed using
unpaired t-test. Values of P,0.05 were considered significant.
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